Jefferson Luís Vieira

Jefferson Luís Vieira

Auto-generated profile, based on publicly available information

Jefferson Luís Vieira

Hospital de Messejana Dr. Carlos Alberto Studart, Brasil; Universidade Federal do Ceará, Brasil; Universidade Christus, Brasil

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
LRLuis Eduardo Paim Rohde
Luis Eduardo Paim Rohde
MMMarcelo Westerlund Montera
Marcelo Westerlund Montera
EBEdimar Alcides Bocchi
Edimar Alcides Bocchi
NCNadine Oliveira Clausell
Nadine Oliveira Clausell
DADenilson Campos de Albuquerque
Denilson Campos de Albuquerque
WMWolney de Andrade Martins
Wolney de Andrade Martins

5 November 2014 in American Journal of Cardiovascular Drugs
Verified
Journal Article
Closed access
PDF file
DMDaniel Medeiros Moreira
Daniel Medeiros Moreira
RSRoberto Leo da Silva
Roberto Leo da Silva
JVJefferson Luís Vieira
Jefferson Luís Vieira
TFTammuz Fattah
Tammuz Fattah
MLMaria Emilia Lueneberg
Maria Emilia Lueneberg
CGCarlos Antonio Mascia Gottschall
Carlos Antonio Mascia Gottschall

26 May 2021 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
FMFabiana Marcondes-Braga
Fabiana Marcondes-Braga
LMLídia Ana Zytynski Moura
Lídia Ana Zytynski Moura
VIVictor Sarli Issa
Victor Sarli Issa
JVJefferson Luis Vieira
Jefferson Luis Vieira
LRLuis Eduardo Rohde
Luis Eduardo Rohde
EMEvandro Tinoco Mesquita
Evandro Tinoco Mesquita
Introdução A última Diretriz de Insuficiência Cardíaca do Departamento de Insuficiência Cardíaca da Sociedade Brasileira de Cardiologia (DEIC/SBC) foi finalizada em março de 2018. A partir de então, houve um importante número de intervenções terapêuticas e abordagens diagnósticas que surgiram ou se consolidaram na prática clínica internacional e na pesquisa clínica. Ao lado disso, a pandemia da COVID-19 trouxe-nos conhecimento sobre o modelo fisiopatológico da agressão miocárdica e muitas dúvidas acerca da continuidade e da segurança dos medicamentos nos pacientes [...] Introdução A última Diretriz de Insuficiência Cardíaca do Departamento de Insuficiência Cardíaca da Sociedade Brasileira de Cardiologia (DEIC/SBC) foi finalizada em março de 2018. A partir de então, houve um importante número de intervenções terapêuticas e abordagens diagnósticas que surgiram ou se consolidaram na prática clínica internacional e na pesquisa clínica. Ao lado disso, a pandemia da COVID-19 trouxe-nos conhecimento sobre o modelo fisiopatológico da agressão miocárdica e muitas dúvidas acerca da continuidade e da segurança dos medicamentos nos pacientes

1 December 2009 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
DMDaniel Medeiros Moreira
Daniel Medeiros Moreira
JVJefferson Luís Vieira
Jefferson Luís Vieira
CGCarlos Antônio Mascia Gottschall
Carlos Antônio Mascia Gottschall

4 January 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
BWBrittany Weber
Brittany Weber
HSHasan Siddiqi
Hasan Siddiqi
GZGuohai Zhou
Guohai Zhou
JVJefferson Vieira
Jefferson Vieira
AKAndy Kim
Andy Kim
AWAnn E. Woolley
Ann E. Woolley
Background: Myocardial injury in patients with COVID‐19 is associated with increased mortality during index hospitalization; however, the relationship to long‐term sequelae of SARS‐CoV‐2 is unknown. This study assessed the relationship between myocardial injury (high‐sensitivity cardiac troponin T level) during index hospitalization for COVID‐19 and longer‐term outcomes. Methods and Results: This is a prospective cohort of patients who were hospitalized at a single center between March and May 2020 with SARS‐CoV‐2. Cardiac biomarkers were systematically collected. Outcomes were adjudicated and stratified on the basis of myocardial injury. The study cohort includes 483 patients who had high‐sensitivity cardiac troponin T data during their index hospitalization. During index hospitalization, 91 (18.8%) died, 70 (14.4%) had thrombotic complications, and 126 (25.6%) had cardiovascular complications. By 12 months, 107 (22.2%) died. During index hospitalization, 301 (62.3%) had cardiac injury (high‐sensitivity cardiac troponin T≧14 ng/L); these patients had 28.6%, 32.2%, and 33.2% mortality during index hospitalization, at 6 months, and at 12 months, respectively, compared with 4.1%, 4.9%, and 4.9% mortality for those with low‐level positive troponin and 0%, 0%, and 0% for those with undetectable troponin. Of 392 (81.2%) patients who survived the index hospitalization, 94 (24%) had at least 1 readmission within 12 months, of whom 61 (65%) had myocardial injury during the index hospitalization. Of 377 (96%) patients who were alive and had follow‐up after the index hospitalization, 211 (56%) patients had a documented, detailed clinical assessment at 6 months. A total of 78 of 211 (37.0%) had ongoing COVID‐19–related symptoms; 34 of 211 (16.1%) had neurocognitive decline, 8 of 211 (3.8%) had increased supplemental oxygen requirements, and 42 of 211 (19.9%) had worsening functional status. Conclusions: Myocardial injury during index hospitalization for COVID‐19 was associated with increased mortality and may predict who are more likely to have postacute sequelae of COVID‐19. Among patients who survived their index hospitalization, the incremental mortality through 12 months was low, even among troponin‐positive patients.

1 January 2016 in JACC: Heart Failure
Verified
Journal Article
Closed access
JVJefferson L. Vieira
Jefferson L. Vieira
GGGuilherme Guimarães
Guilherme Guimarães
PAPaulo A. de Andre
Paulo A. de Andre
FCFátima D. Cruz
Fátima D. Cruz
Paulo SaldivaPaulo Saldiva
Paulo Saldiva
EBEdimar A. Bocchi
Edimar A. Bocchi